The activity of human replication protein A (RPA) in DNA replication and repair is regulated by phosphorylation of the middle RPA2 subunit. It has previously been shown that up to nine different N-terminal residues are modified in vivo and in response to genotoxic stress. Using a novel antibody against phospho-S29, a moiety formed by cyclin-Cdk, we observed that RPA2 was phosphorylated during mitosis in non-stressed cells. Robust phosphorylation of S29 was also seen in interphase cells following treatment with the DNA-damaging agent camptothecin, a rare example of stress stimulating the modification of a repair factor by cyclin-Cdk. RPA2 phosphorylation is regulated both in cis and trans. Cis-phosphorylation follows a preferred pathway. That is, the initial modification of S33 by ATR stimulates subsequent phosphorylation of Cdk sites S23 and S29. These events then facilitate modification of T21 and extreme Nterminal sites S4 and S8, likely by DNA-PK. Our data also indicate that the phosphorylation of one RPA molecule can influence the phosphorylation of other RPA molecules in trans. Cells in which endogenous RPA2 was 'replaced' with a double S23A/S29A-RPA2 mutant were seen to have an abnormal cell cycle distribution both in normal and in stressed cells. Such cells also showed aberrant DNA damage-dependent RPA foci, and had persistent staining of γ H2AX following DNA damage. Our data indicate that RPA phosphorylation facilitates chromosomal DNA repair. We postulate that the RPA phosphorylation pattern provides a means to regulate the DNA repair pathway utilized.
The activity of human replication protein A (RPA) in DNA replication and repair is regulated by phosphorylation of the middle RPA2 subunit. It has previously been shown that up to nine different N-terminal residues are modified in vivo and in response to genotoxic stress. Using a novel antibody against phospho-S29, a moiety formed by cyclin-Cdk, we observed that RPA2 was phosphorylated during mitosis in non-stressed cells. Robust phosphorylation of S29 was also seen in interphase cells following treatment with the DNA-damaging agent camptothecin, a rare example of stress stimulating the modification of a repair factor by cyclin-Cdk. RPA2 phosphorylation is regulated both in cis and trans. Cis-phosphorylation follows a preferred pathway. That is, the initial modification of S33 by ATR stimulates subsequent phosphorylation of Cdk sites S23 and S29. These events then facilitate modification of T21 and extreme Nterminal sites S4 and S8, likely by DNA-PK. Our data also indicate that the phosphorylation of one RPA molecule can influence the phosphorylation of other RPA molecules in trans. Cells in which endogenous RPA2 was 'replaced' with a double S23A/S29A-RPA2 mutant were seen to have an abnormal cell cycle distribution both in normal and in stressed cells. Such cells also showed aberrant DNA damage-dependent RPA foci, and had persistent staining of γ H2AX following DNA damage. Our data indicate that RPA phosphorylation facilitates chromosomal DNA repair. We postulate that the RPA phosphorylation pattern provides a means to regulate the DNA repair pathway utilized.
Replication Protein A (RPA) is a heterotrimeric single-stranded DNA-binding factor that is critical for the three Rs of eukaryotic DNA enzymology: DNA replication, DNA recombination and DNA repair (1, 2) . For DNA replication, study of cellular and viral model systems demonstrate that RPA is needed both for origin denaturation and replication elongation, in the latter case to facilitate the switch from DNA polymerase α to DNA polymerase δ during Okazaki fragment synthesis (3) . RPA acts in homologous recombination (HR) to stimulate DNA annealing using physical interactions with Rad52 (4-7), and in HR-mediated DNA repair likely employing specific interactions with BRCA2 (8, 9) . RPA is a required factor in both the nucleotide excision (10, 11) and mismatch repair pathways (12, 13) , and in somatic hypermutation (14) . Because of these many roles, it is of significant interest to understand the mechanisms that regulate RPA activity.
Of the ~70 kDa (RPA1), 30 (RPA2), and 14 kDa (RPA3) subunits, human RPA is subject to extensive phosphorylation on RPA2 (2) , and at one RPA1 site (15) . The N-terminal 33 residues of RPA2 undergo both cell-cycle-and stressdependent phosphorylation on ~nine sites (Fig.  1A) which are thought to exist in an unstructured conformation (16, 17) . S23 and S29 are constitutively modified during mitosis by cyclin B-Cdk1 (18, 19) , and have been suggested to be partially modified beginning at the G1/S boundary by the cyclin A-Cdk2 complex (18, 20, 21) . These two residues may also undergo heightened phosphorylation in response to UV irradiation (22) . The T21 and S33 residues are consensus sites for phosphatidylinositol 3-kinase-like kinase (PIKK) family members (ATM, ATR, and DNA-PK) that signal the presence of DNA damage and replication stress. Under DNA damage conditions, the phosphorylation of T21 is apparently catalyzed by ATM, DNA-PK, and probably ATR (22, 23) . Olson et al. have concluded that S33 is modified by ATR (24) . The remaining sites (S4, S8, S11, S12, and S13) are phosphorylated in response to genotoxic stress although the responsible kinase(s) in vivo has not yet been identified. However, all can be modified by DNA-PK in vitro (22) . Others have also shown the involvement of DNA-PK in supporting RPA2 hyper-phosphorylation (25, 26) .
RPA activity in vivo is regulated by phosphorylation. RPA containing RPA2 mutations that mimic hyper-phosphorylation selectively prevent the association of RPA with replication centers but not repair foci (24, 27) . Similarly, others have found that ATR-dependent phosphorylation of RPA inhibits DNA synthesis following UV irradiation (24) . These effects are likely mediated by RPA phosphorylation regulating its association with other factors. It has been found that treatment of cells with camptothecin (CPT) led to dissociation of RPA:DNA-PK complexes, an event presumably mediated by RPA phosphorylation (25) . Test of the mitotic RPA species (mentioned above) found that it had reduced affinity for ATM and DNA polymerase α, as compared to non-phosphorylated RPA (19) . The Wold laboratory similarly observed that RPA phosphorylation reduced its interaction with DNA polymerase α and SV40 T antigen, but increased association with p53 (2) .
Along with being a substrate for ATR, RPA is also instrumental in signaling the presence of replication stress, and is an essential component of a pathway that activates the kinase (28, 29) . The primary activation pathway during DNA replication stress apparently involves binding of RPA to ssDNA formed after DNA polymerase stalling and continued movement of the replicative helicase. This persistent RPA-ssDNA intermediate supports binding of the ATR-ATRIP complex and, in combination with other factors, leads to activation of the ATR kinase (30) , which then phosphorylates RPA2 at S33. ATR is also regulated across the cell cycle with the processing of double-strand breaks (DSBs) to RPA-ssDNA intermediates (that allow kinase activation) occurring only in the S and G2 phases when Cdk kinase activity is significant (31) . Interestingly, test of human cell extracts indicated that RPA phosphorylated by Cdk stimulates modification by DNA-PK (32) . Such data indicate that RPA phosphorylation events catalyzed by Cdk, PIKK, and other kinases may be interdependent.
Because of the importance of RPA phosphorylation, we employed phospho-specific antibodies, including a novel antibody recognizing the S29 cyclin-Cdk site, to examine the modification pattern of RPA2 at five of the Nterminal sites. We find that, under conditions of genotoxic stress, the actions of cyclin-Cdk and PIKK in causing RPA hyper-phosphorylation are synergistic, and both are necessary to cause subsequent modification of extreme N-terminal RPA2 residues. Cells expressing RPA2 mutated at the two cyclin-Cdk sites had more intense RPA2 staining and increased persistence of γH2AX foci following genotoxic stress. These data indicate that RPA phosphorylation stimulates DNA repair.
Experimental Procedures
Cell culture-U2-OS cells were cultured in McCoy's medium containing 10% fetal bovine serum (FBS). Cell lines positive (MO59K) or null (MO59J) for the DNA-PK catalytic subunit were cultured in DMEM/F12 (1:1; v:v) containing 10% FBS. As required, cells were treated for 1 h with 2 µM CPT (Sigma) or 75 µg/ml bleomycin (Ble; Calbiochem). For synchronization experiments, cells were arrested in prometaphase by treatment with 100 ng/ml nocodazole (Sigma) for 14 to 16 h, and the mitotic cells isolated by shake-off. To release cells from the mitotic block, nocodazolearrested cells were washed in phosphate-buffered saline (PBS), released in medium devoid of nocodazole, and then collected at various times post-release. CPT or Ble treatment occurred 1 h prior to harvest.
When testing kinase activity against mitotic RPA, cells were incubated with 100 ng/ml nocodazole and 200 µM roscovitine (cyclin-Cdk inhibitor; Calbiochem) for 16 h. To examine the role of cyclin-Cdk in phosphorylation of RPA during genotoxic stress, cells were first treated with 50 or 200 µM roscovitine for 45 min, followed by treatment with 2 µM CPT (in the continued presence of roscovitine) for 1 h. In order to inhibit ERK activation, cells were pretreated with U0126 (a kind gift from Dr. Paolo Mignotti) at 10 µM for 1 h. Genotoxic stress was induced by treatment with 2 µM CPT for 1 h in the continued presence of the inhibitor.
Transient transfections were performed using Effectene (Qiagen). Kit reagents were used at onethird of the recommended quantity, and cells were incubated with these reagents for 12 h followed by a change of medium. Cells were collected for analysis 48 h post-transfection.
Lambda phosphatase treatment-for phosphatase treatment, cells were lysed in lambda protein phosphatase buffer (New England Biolabs) containing 1% Triton X-100, 2 mM MnCl 2 and protease inhibitor cocktail tablet (Roche). Cell lysates (20 µg of protein) were then incubated with 400 U of lambda protein phosphatase for 30 min at 30°C or mock treated in the presence of protein phosphatase inhibitors (0.5 mM Na 3 VO 4 , 10 mM β-glycerophosphate and 50 mM NaF). Lysates were examined by Western blotting.
RPA2 mutagenesis and retrovirus expression-The
Myc-tagged RPA2 expression vector was previously described (27) . This vector was used to generate the Ser to Ala or Asp phosphorylation site mutations (Fig 1B) using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). Topstrand primers were as follows; S23A (5' CTA CAC GCA GGC CCC GGG GGG CT 3'); S23D (5' TAC ACG CAG GAC CCG GGG GGC T 3'); S29A (5' GGG GGG CTT TGG AGC ACC CGC  ACC TTC TC 3'), S29D (5' GGG GGG CTT  TGG AGA TCC CGC ACC TTC TC 3'); T21A  (5' CCG GCG GCT ACG CAC AGT CCC CGG  G 3' ). The S23A-RPA2 was used as a template to generate S23A/S29A double mutant, whilst S23D-RPA2 was the template to prepare the S23D/S29D double mutant. Similarly, we used the S33A-RPA2 mutant (Vassin, V., Anantha, R.W., and Borowiec, J.A., in preparation) as the template to prepare the T21A/S33A double mutant.
To analyze the effect of Cdk site mutation on mitotic RPA2 phosphorylation and hyperphosphorylation during genotoxic stress, the Myctagged versions of the Cdk site mutants were transiently transfected into U2-OS cells (see Fig  2C) . For all other analyses, untagged versions of RPA2 were generated. In order to do so, the mutated version of RPA2 was amplified by PCR using primers (forward, 5' TGC AGA TAT CCA  GCA CAG TGG CGG CCG CTC GAG 3';   reverse 5' AAT GGA TCC TTA TTC TGC ATC  TGT GGA TTT AAA ATG GTC ATC ATC C 3') that contain NotI and BamHI sites in the forward and reverse primers, respectively. PCR products were then subcloned into the NotI and BamHI sites on the pRetro-Off retroviral vector (Clontech). The mutants tested are shown (Fig. 1B) . Production of retroviruses containing the RPA2 expression cassette was performed in Phoenix cells (obtained from G. Nolan; Stanford University) using the Phoenix Retroviral Helper dependent protocol (http://www.stanford.edu/group/nolan/protocols/pr o_helper_dep.html).
U2-OS cells at 40% confluency were infected with the desired retrovirus for 48 h in the presence of 2 µg/ml doxycycline (to inhibit ectopic untagged-RPA2 expression). Clones resistant to puromycin (1 µg/ml) were isolated, and assayed for expression of the ectopic RPA2. This was done by Western blot analysis, after silencing of endogenous RPA2 (see below), both in the presence and absence of doxycycline. Clones that showed strong doxycycline-regulated induction of RPA2 were selected and amplified for further analysis.
RPA2 replacement strategy and silencing-For replacement of endogenous RPA2, retrovirallyinfected U2-OS clones were first grown for 48 h in media lacking doxycycline to allow ectopic RPA2 expression (Fig. 1C ). The endogenous RPA2 was then down-modulated using an siRNA molecule (top strand sequence; 5' AAC CUA GUU UCA CAA UCU GUU 3') targeting the 3'-UTR of the RPA2 mRNA (27) . Silencing was achieved using Hiperfect (Qiagen) as per the manufacturer's instructions, with cells tested 72 h posttransfection. Representative levels of RPA2 following down-modulation and ectopic induction by Western are shown (Fig. 1D) , demonstrating the efficiency of the silencing and replacement procedure. A parallel investigation using immunofluorescence microscopy demonstrates that the 'replaced' cells each have similar levels of ectopic RPA2 expression ( Supplementary Fig. 1 ). Immunofluorescence microscopyFor visualization of RPA2 foci, cells were split onto coverslips 48 h post-silencing. Cells were then either mock or CPT treated 24 h later. For treatment, cells were incubated with 2 µM CPT for 1 h, followed by washing with PBS and extraction with 0.5% (v:v) Triton X-100 in CSK buffer (10 mM Hepes-KOH pH 7.4; 300 mM sucrose; 100 mM NaCl; 3 mM MgCl 2 ) for 2 minutes on ice. Cells were then fixed with 4% (w:v) paraformaldehyde either immediately (0 h) or 8 h post-CPT treatment. γH2AX foci were generated by treatment of replaced cells with either 5 µM CPT (70 h post silencing) or 30 µg/ml Ble (56 h post silencing), in both cases for 2.5 h. Cells were then washed twice with PBS, and extracted and fixed either immediately (0 h), or at 8 h (CPT) or 15 h (Ble) post-wash. Coverslips were then stained with primary and secondary antibodies. Quantitation of foci intensity was performed using IPLab software (RPA2; BD Biosciences) or ImageJ (γH2AX; NIH). In order to observe RPA2 expression patterns in wt-versus S23A/S29A-RPA2 clones, cells were directly fixed and stained with a monoclonal RPA2 antibody.
Immunoblotting and antibodies-
Flow cytometry-Trypsinized cells were washed with PBS and fixed by drop-wise addition into a 10x volume of ice-cold 70% ethanol. Following an overnight incubation at 4˚C, cells were pelleted and stained with 0.5 ml of a solution containing PBS, 0.02% (w/v) propidium iodide (Sigma), 0.1% (v/v) Triton X-100 and 200 µg/ml RNase A, for 15 min at 37°C followed by cell sorting. FACS was performed on a Becton Dickinson flow cytometer using the Cell Quest software. Cell cycle analysis was performed using the Mod-Fit software.
RESULTS

Phosphorylation of the RPA2 S29 cyclin-Cdk site in vivo.
Characterization of the effect of genotoxic stress on the human RPA phosphorylation pattern has been aided by the recent development of phospho-specific antibodies directed against the various phosphorylation sites. At the time of this study, antibodies were commercially available against pT21, pS33, and doubly-phosphorylated pS4/pS8 (Fig. 1A) . To add to this collection, we developed an antibody recognizing pS29, a cyclinCdk site reported to be modified constitutively during mitosis.
Like the anti-pS33, and -pT21 RPA2 antibodies, the pS29 antibody was observed to show little reactivity to lysates prepared from control U2-OS cells ( Fig. 2A) . To induce genotoxic stress, cells were treated with CPT which indirectly causes damage (e.g., DSBs) through the collision of DNA replication forks with trapped topoisomerase I-DNA complexes (33) . Incubation of cells with CPT caused the appearance of a hyper-phosphorylated wt-RPA2 species (lane 11), which was also significantly reactive to each of the phospho-specific antibody (lanes 2, 5, and 8; marked 'H'). Pre-treatment of the lysates with λ phosphatase caused the disappearance of the hyper-phosphorylated RPA2 species (using a general RPA2 antibody) and a loss of reactivity by each of the phospho-specific antibodies. For the pS33 and pT21 antibodies, these data confirm previous reports showing high specificity of these antibodies (e.g., ref. 24). The pS4pS8 antibody was previously demonstrated by our laboratory to lose reactivity of hyperphosphorylated RPA2 following phosphatase treatment (27) .
To further verify the specificity of the novel pS29 antibody, we employed stable cell lines that allow inducible expression of an untagged version of wild-type (wt) or mutant RPA2. Expression of this ectopic RPA2 is coupled with RNAi-mediated knockdown of endogenous RPA2 by targeting a 3' UTR sequence contained only in the endogenous RPA2 message. In this manner, the endogenous RPA2 is replaced with an ectopic version. Note that previous studies have found that the ectopic RPA2 is incorporated into heterotrimeric RPA, with the level of RPA2 apparently regulating the total cellular level of RPA (27, 34, 35) . Using clonal U2-OS cells, the expression of either wt-RPA2 or a double S23A/S29A-RPA2 mutant was induced, and the endogenous RPA2 protein levels then down-modulated by treatment with a specific siRNA molecule. Lysates were prepared from cells experiencing genotoxic stress, or mitotic cells. Incubation of cells with CPT again caused the appearance of a hyper-phosphorylated wt-RPA2 species that was also recognized by the anti-pS29 antibody (Fig. 2B , lane 1). The S23A/S29A mutation reduced the amount of hyper-phosphorylated RPA2 and reactivity to the pS29 probe (lane 2). Examining mitotic RPA2, while the wild-type subunit generated a strong pS29 signal, the S23A/S29A mutation nearly completely caused the loss of the mRPA2 species and the pS29 signal (lanes 3 and 4).
We tested S29 modification across the cell cycle. U2-OS cells were arrested in mitosis with nocodazole, and aliquots of the arrested cells then released into the cell cycle for 4 and 8 h (early and late G1 phases), 16 h (S phase), or 20 h (a mixture of S and G2 cells) (Fig. 2C ). Lysates from these and mitotic cells (0 h) were subjected to Western blot analysis using antibodies directed to pS29-RPA2 or total RPA2. In mitotic cells, the RPA2 pool was present in three bands, a basal (nonphosphorylated) form and two slower-migrating species. Of the three mitotic RPA species, the pS29-antibody recognized the slower-migrating forms. When cells were released into the cell cycle, we did not observe any significant reactivity of RPA2 to the pS29 antibody in G1, S, or G2 cells. Along with verifying the usefulness of these antibodies, these data indicate that S29 is phosphorylated both during mitosis and in interphase only in response to genotoxic stress.
Effect of cyclin-Cdk site mutation on formation of mitotic
and hyper-phosphorylated RPA2. Expression of an S23A/S29A-RPA2 mutant in vivo was previously found to prevent RPA2 phosphorylation (20) , but did not reveal the relative importance of each site or the cell-cycle dependence of phosphorylation. We therefore examined the relative importance of the S23 and S29 sites in supporting mitotic RPA phosphorylation in vivo. To address these questions, we first tested Myc-tagged RPA2 molecules with one or both sites mutated to alanine (to prevent phosphorylation). Previous test of myc-tagged RPA2 indicate that the subunit is efficiently incorporated into heterotrimeric RPA (27) .
U2-OS cells were transiently transfected with S23A-RPA2, S29A-RPA2, doubly-mutated S23A/S29A-RPA2, or the control wt-RPA2. Following transfection, lysates were prepared from nocodazole-arrested mitotic cells and probed by Western analysis for the Myc tag (Fig. 2D) . Similar to the endogenous RPA2 in mitotic cells (see Fig. 2C ), the Myc-tagged wt-RPA2 had three bands corresponding to the basal RPA2 (marked 'B'), mitotic RPA2 (+2p), and a form that migrated between these two species (+1p) (lane 1). The S23A and S29A single mutants resulted in a loss of the slowest-migrating species (lanes 2 and 3), and the double S23A/S29A mutant gave rise to only a single band that migrated identically to nonphosphorylated RPA2 (lane 4).
It is important to note that the migration of RPA2 in SDS-PAGE is governed by the RPA phosphorylation state (22) . That is, addition of one phosphate residues causes a small reduction in RPA2 mobility, two phosphates provides a greater reduction, up until the addition of ~five or more phosphates which cause RPA2 to migrate in the hyper-phosphorylated position. Thus, the observed changes in the RPA2 migration pattern are consistent with the +2p species being phosphorylated at two sites, S23 and S29. The S23A and S29A single mutants each contain one phosphate at the non-mutated Cdk site. The comigration of the S23A/S29A mutant with basal RPA2 indicates a lack of phosphorylation of this species in mitotic cells.
To provide additional evidence for these conclusions, we also tested constructs in which the same sites were mutated to aspartate (to mimic phosphorylation). The negative charge on asparate reduces RPA2 mobility similar to that of a phosphate residue (e.g., ref. 27). The S23D and S29D single mutants each generated two mitotic bands that co-migrated with the upper two species seen for wt-RPA2 (Fig. 2D , lanes 5 and 6). The S29D mutant showed a greater amount of phosphorylation (i.e., the +2p species) compared to the S29A mutant (i.e., the +1p species), suggesting that the negative charge on the D29 residue facilitates subsequent phosphorylation of S23. The double S23D/S29D mutant gave rise to only a single band that migrated similarly to the wt-RPA2 +2p species (lane 7). These data demonstrate that both S23 and S29 are modified during mitosis. The lack of detection of any mitotic S23A/S29A-RPA2 species migrating more slowly than basal RPA2, and the presence of only a single S23D/S29D-RPA2 form, argues that S23 and S29 are likely the only residues significantly phosphorylated in mitotic RPA2. That is, if other positions were modified in mitotic cells, these modifications would be expected to cause a mobility shift in either S23A/S29A-or S23D/S29D-RPA2.
Cyclin-Cdk complexes phosphorylate S29 during mitosis and under conditions of genotoxic stress.
S23 and S29 are known Cdk sites, with both cyclin A-Cdk2 and cyclin B-Cdk1 are competent to phosphorylate S23 and S29 in vitro (20, 32, (36) (37) (38) (39) . We used the anti-pS29 antibody to further test if Cdk kinases also phosphorylate endogenous RPA2 protein in vivo during mitosis and following genotoxic stress. We tested roscovitine, a highly selective inhibitor of Cdk1 and Cdk2 (40) . Because pS29 is only formed in non-stressed cells during mitosis, we merely enriched for mitotic cells by an overnight treatment with nocodazole, yielding a robust pS29 signal (Fig. 3A, lane 1) . Treating U2-OS cells with nocodazole and roscovitine abolished the mitotic RPA2 species as well as the associated phosphorylation of S29 (lane 2). These data are consistent with the hypothesis that RPA2 is a substrate for cyclin BCdk1 during mitosis.
Roscovitine had a more complex effect on asynchronous cells undergoing genotoxic stress. In the absence of roscovitine, lysates from cells treated with CPT caused the formation of hyperphosphorylated RPA2 (marked 'H'), and a great increase in the pS29, pS33, pT21, and pS4/pS8 signals (Fig. 3B, lane 4) . Pre-incubation of cells with roscovitine (50 or 200 µM for 45 min; (lanes 2 and 3, respectively) before CPT treatment greatly reduced the amount of hyperphosphorylated RPA2. Roscovitine also caused a strong decrease in the pS29 signal, both at the intermediate (marked 'I) and hyperphosphorylated positions. Similar decreases in the pT21 and pS4/pS8 signals were also noted. In the case of S33, we found that roscovitine caused a selective reduction in pS33 in the hyperphosphorylated RPA2 species, but did not reduce the pS33 signal in RPA2 of a low (i.e., quickly migrating; marked 'L') phosphorylation state. These data suggest that inhibition of S23 and S29 phosphorylation by roscovitine reduces subsequent modification events (e.g., at S4 and S8), precluding conversion of pS33-RPA2 to the hyperphosphorylated state. This point is examined more rigorously below.
Analysis of the RPA2 N-terminal region for phosphorylation motifs (i.e., using Scansite; ref. 41) indicated that S23 and S29 are also potential sites for extracellular signal-regulated kinases (ERK1/2) (data not shown). Although normally associated with mitogen activation, signaling through the ERK pathway has been found to be induced in response to DNA damage (reviewed in ref. 42 ). To test the possibility that ERK1/2 also phosphorylates S29 under conditions of genotoxic stress, we employed the MEK inhibitor U0126. Addition of U0126 to CPT-treated U2-OS cells greatly reduced the level of ERK phosphorylation by MEK (Fig. 3C) . However, U0126 did not have significant effects on RPA2 hyperphosphorylation, nor on the level of pS29-RPA2. We therefore conclude that S29 phosphorylation in response to DNA damage is catalyzed by a cyclinCdk complex. Although this event likely occurs early in the DNA damage signaling pathway, it nevertheless represents a rare example of genotoxic stress stimulating phosphorylation of a DNA repair protein by cyclin-Cdk.
Lack of DNA-PK reduces RPA phosphorylation at all detectable RPA2 sites. We examined the role of DNA-PK in the phosphorylation of various RPA2 residues. We employed two paired cell lines that are either wild-type (M059K) or null (M059J) for expression of the DNA-PK catalytic subunit (DNA-PK CS ; ref. 43) . Following mock-treatment or incubation with CPT, lysates from these lines were prepared and the phosphorylation status of the different RPA2 sites examined by Western analysis. Very little RPA2 phosphorylation was seen in either of the mock-treated cell lines, with the exception of pS29 migrating at an intermediate position, likely arising from mitotic cells (Fig. 3D,  lanes 1 and 2) . Following exposure to CPT, cells expressing DNA-PK CS showed significant RPA2 hyper-phosphorylation, and formation of pS33, pS29, pT21, and pS4pS8 (lane 3). In contrast, cells lacking DNA-PK CS were severely deficient in the phosphorylation of S4/S8 and T21 (lane 4). Loss of the pS33 and pS29 signals was also noted, but only in the hyper-phosphorylated position. For both modifications, the presence of DNA-PK CS did not have any notable effects on the pS33 and pS29 signals in the intermediate position. Combined with past studies examining RPA phosphorylation by DNA-PK (22, 23) , these data are consistent with the proposal that DNA-PK is a primary but not sole kinase competent to phosphorylate T21 and S4/S8 in vivo in response to CPT treatment. Because there is no indication that DNA-PK phosphorylates S29 (above; ref. 21) or S33 (24) in vivo, we believe that the reduction in pS29 and pS33 formation in cells lacking DNA-PK CS is a consequence of the RPA phosphorylation state affecting the phosphorylation of other RPA molecules in trans (see below).
Inter-relationship between RPA2 phosphorylation events. To comprehensively examine the interplay between RPA2 phosphorylation events, we tested the effect of various RPA2 mutations. The mutations were located in either the Cdk sites (S23 and S29) or the PIKK sites (T21 and S33), with the RPA2 mutants inducibly expressed from stable U2-OS cell clones (see Fig. 1C ). Following 'replacement' of the endogenous RPA2, cells were treated with CPT (2 µM for 1 h). The lysates were separated on gels that allowed clear separation of the different phosphorylation species, and analyzed by Western. Control experiments indicated that, in the absence of CPT, replacement per se does not cause RPA hyper-phosphorylation (Fig. 4A) .
We first examined the relative importance of the cyclin-Cdk and PIKK sites in supporting the formation of hyper-phosphorylated RPA2 in response to CPT. Cells expressing RPA2 with double mutations in the cyclin-Cdk (S23A/S29A) or PIKK (T21A/S33A) sites were analyzed (Fig.   4B ). While either double mutant inhibited formation of pS4pS8-RPA2 and RPA2 hyperphosphorylation, the mutation of the two PIKK sites caused a greater loss of the pS4pS8 signal (lane 2). Regarding the S33 site, it was seen that the double Cdk site mutant caused a significant reduction in the level of pS33 in hyperphosphorylated RPA2 ('H'), while not inhibiting the pS33 signal migrating near basal RPA2 ('L; lane 3). Mutation of both PIKK sites resulted in a significant diminution of pS29. The level of pS33 in cells expressing the T21A/S33A-RPA2 mutant, and the amount of pS29 in S23A/S29A-RPA2 cells was low, demonstrating the efficiency of the silencing procedure. Note also that the pS4pS8 signal seen for wt-RPA2 is significantly greater than a simple addition of the signals seen for each double mutant protein. These data reveal that the two kinase pathways (Cdk and PIKK) have a synergistic action on RPA2 hyperphosphorylation.
To further dissect the role of individual amino acids in supporting RPA phosphorylation, we studied single mutants for each class of sites. The effect of Cdk site mutations was examined. In response to CPT, the control wt-RPA2 showed robust phosphorylation of S33, S29, T21, and S4/S8, (Fig. 4C, lane 1) . The vast bulk of the phosphorylated RPA2 migrated in the hyperphosphorylated form. The S23A/S29A double mutation had significant inhibitory effects on S4/S8 and T21 modification, and on the generation of hyper-phosphorylated RPA2 (Fig. 4C, lane 2) . The level of pS33 migrating at the position of hyper-phosphorylated RPA2 was also strongly reduced in intensity, although the pS33-positive species that migrated slightly above basal RPA2 (marked 'L') persisted, similar to the effect seen above (Fig. 4B, lane 3) . In other studies, we have found that HU treatment caused the formation of a pS33-positive RPA2 species that migrates only slightly above non-phosphorylated RPA2, indicating that S33 is the first, or one of the first, RPA2 residues to be modified in response to genotoxic stress (Supplementary Fig. 2 ). Because RPA2 migration on SDS-PAGE is governed by the RPA phosphorylation state (22; see above), the slight reduction in the 'L' form of pS33-RPA2 relative to basal non-phosphorylated indicates that S33 is probably the only residue modified on this RPA2 species. Logically, the fact that pS33 is by guest on November 17, 2017 http://www.jbc.org/ Downloaded from present in RPA2 of a low phosphorylation state also demonstrates that S33 can be one of the first residues modified in response to CPT treatment (see also Discussion). Overall, these data suggest that the Cdk site double mutation does not greatly affect initial formation of the pS33-RPA2, but rather prevents additional phosphorylation events including those at S4, S8 and T21 leading to RPA2 hyper-phosphorylation.
We tested the possibility that phosphorylation of the two Cdk sites stimulates RPA2 hyperphosphorylation. Cells were replaced with wt-RPA2, the S23A/S29A variant, or an RPA2 mutant containing two aspartate substitutions at the Cdk phosphorylation sites (S23D/S29D-RPA2). Concerning the S23D/S29D mutant, it has been previously found that asparate (or glutamate) residues often mimic phosphorylated serines/threonines. We successfully used an asparate-substituted RPA2 as a surrogate 'phospho-protein' in an earlier examination of RPA phosphorylation (27) . Following replacement, the cells were examined under control conditions, or after exposure to CPT (2 µM for 1 h). Testing the RPA2 status by Western, we found that the RPA2 variants from non-stressed lysates had a single major band migrating in the basal RPA2 position (Fig. 4D ). As seen above (see Fig. 2D ), S23D/S29D-RPA2 migrated on SDS-PAGE with reduced mobility (Fig. 4D, lane  2) . Under conditions of genotoxic stress, wt-RPA2 but not S23A/S29A-RPA2 showed the appearance of the hyper-phosphorylated form ('H'; Fig. 4D , lanes 4 and 6, respectively), as seen above. Importantly, the S23D/S29D mutant also showed the appearance of a hyper-phosphorylated form (Fig. 4D, lane 5) . Thus, a variant which mimics RPA2 phosphorylated by Cdk facilitates further phosphorylation events seen after genotoxic stress. These data provide further support for the conclusion that RPA2 phosphorylation events are inter-related.
Of the S23A-and S29A-RPA2 single mutants, S23A had significantly stronger effects on the formation of pS33, pT21, and pS4/pS8 (Fig.  4C, lane 4) , with the reduction in modification of these sites comparable to that seen with the double mutant. The S23A mutation also reduced the amount of pS29, indicating that Cdk-mediated phosphorylation of S23 stimulates co-modification of S29. The S29A mutation had only weak effects on the various RPA2 modifications (lane 3), again attesting to the lack of effect of RPA2 mutations on antibody recognition (see also below). Similar to the Cdk double mutant, the S23A single mutant showed a significant pS33 signal migrating at the 'L' position. These data indicate that the inability to phosphorylate the two Cdk sites, primarily S23, strongly inhibits modification of all other detectable residues including the distal S4 and S8 sites.
Considering the importance of the two PIKK sites in response to CPT, the T21A/S33A double mutation strongly inhibited modification of S29, both at the hyper-phosphorylated and intermediate positions (Fig. 4E, lane 4 ; see also Fig. 4B , lane 2). In addition, the mutation also abolished detectable formation of pS4/pS8 and hyperphosphorylated RPA2. To determine the relative importance of the two amino acid changes in causing reduction of pS29 and pS4/pS8, we also tested T21A and S33A single mutants. Comparing the two mutations, both similarly reduced formation of pS4pS8 and pS29 to levels intermediate between that of wt-RPA2 and T21A/S33A-RPA2. Somewhat surprisingly, even though pT21 is only found in the hyperphosphorylated position, the T21A mutation also had severe inhibitory effects on the level of pS33 in the hyper-phosphorylated position ('H'), although pS33 in RPA2 of a low phosphorylation state ('L') was unaffected. Similarly, mutation of T21 did not alter the level of pS29 migrating at the intermediate position. Therefore, these data indicate that phosphorylation of T21 most strongly influences events occurring late in the RPA2 phosphorylation pathway.
It is unlikely that the T21A mutation creates a defect in the general conformation of the RPA2 Nterminus, because this region is thought to be unstructured (16, 17) . It is also highly unlikely that antibody recognition of any of the RPA2 phosphoresidues is directly affected by mutation of other sites for the following reasons. pS4pS8; the immunizing peptide used to generate the antibody did not contain T21 or other residues to the Cterminal (personal communication; E. McIntush, Bethyl Laboratory). pS29; the T21A/S33A mutation did not affect recognition of the phospho-epitope by this antibody because this mutation affected neither the total level of mitotic by guest on November 17, 2017 http://www.jbc.org/ Downloaded from RPA2 nor pS29-RPA2 (lane 2, Supplementary  Fig. 3) . Similarly, while the S23A mutation changed the position of mitotic RPA2 and the migration of the primary pS29 band, it was nevertheless efficiently detected by the pS29 antibody (lane 3). pS33; we demonstrated above that mutation of the adjacent Ser residue (S29A) did not alter the level of pS33 ( Figure 4C ). The next closest residue is ten amino acids away (S23), making it highly unlikely that S23 or T21 would be a determinant in the pS33 recognition motif. This conclusion is strengthened by the finding that, for both the S23A and T21A single mutants, the 'L' form of pS33 was recognized at least as well as that of the wild-type. It must be noted that although the S23A mutation reduced the level of pS33, this mutation also abolished RPA2 hyperphosphorylation as assayed with a monoclonal antibody that does not target phosphorylated residues. Thus, the reduction of the pS33 signal is a consequence of the general loss of RPA phosphorylation. pT21; a peptide containing RPA2 residues 16 to 26 was used to generate the antipT21 antibody (Abcam representative, personal communication). This is consistent with the fact that the S29A mutation did not affect formation of pT21, indicating that this mutation does not affect recognition of the epitope (Figures 4C). While the S23A mutation could affect formation of pT21, the strong effect on RPA2 hyper-phosphorylation (using the general antibody) and on pS4/pS8 formation ( Figure 4C ) indicate that the loss of pT21 is caused by the S23A mutation causing a great reduction in the overall phosphorylation of RPA2. It must be emphasized that, in all cases where a particular mutation had an effect on the level of hyperphosphorylated RPA2, this effect was also seen when using a general RPA2 antibody. These data demonstrate that the information obtained using the phospho-specific antibodies in combination with the various RPA2 mutations yields valid data.
Cell-cycle dependence of RPA2 phosphorylation in response to genotoxic stress. We have shown that phosphorylation of cyclin-Cdk sites influences the modification of non-Cdk sites on RPA2. Because Cdk2 activity is strongly up-regulated beginning at the G1/S transition, it can be predicted that the RPA phosphorylation pattern in response to genotoxic stress will be cell-cycle dependent. We tested this hypothesis using either CPT or Ble, agents which have different mechanisms of action. CPT indirectly causes damage through the collision of DNA replication forks with trapped topoisomerase I-DNA complexes (33) . In contrast, Ble directly causes single-and double-strand DNA breaks (44) (Fig. 5A) . For 1 h prior to harvest, cells were treated with either CPT or Ble, and the resulting lysates analyzed by Western for total RPA2, for specific phosphorylated RPA2 residues, or for γH2AX (a DNA damage marker).
Although the level of γH2AX is not a direct quantitative measurement of the amount of DNA damage, at least at moderate to high levels of DSBs (45), it is nevertheless a useful indicator of the overall extent of damage and the relative amount of DNA repair. Although it is conceivable that defects in DNA damage signaling could affect γH2AX formation and thereby complicate our analysis, current evidence indicates that RPA phosphorylation does not have obvious effects on checkpoint activation (e.g., refs. 24 and 46; V.M.V. and J.A.B., unpublished observations).
Testing CPT, we found no significant RPA phosphorylation in G1 cells at 4 or 8 h ( Fig. 5B ; lanes 2 and 4), apart from a slight pS4pS8 signal. In contrast, the 16 h S phase sample showed a very strong signal for pS29, pS33, pT21, and pS4pS8 (lane 6). These signals decreased slightly at the 20 h time point as an increased portion of cells entered G2 (lane 8). The increase in RPA phosphorylation was CPT-dependent as no significant phosphorylation of RPA2 (or H2AX) was observed in 16 and 20 h samples prepared from mock-treated cells (lanes 9 and 10).
Adding Ble to G1 cells did not cause significant RPA2 modification except for a weak pS4pS8 signal ( Fig. 5B; lanes 1 and 3) . Even so, robust formation of γH2AX was detected demonstrating the presence of a high level of DSBs. S-phase cells treated with Ble had only a minor increase in RPA phosphorylation, specifically of the pS29 and pS33 signals (lane 5). The level of RPA phosphorylation in these cells was dramatically less than RPA from S-phase cells treated with CPT (lane 6), even though the level of DSBs caused by Ble was significantly greater as indicated by the markedly higher γH2AX levels. When cells in late S and G2 were treated with Ble (20 h), T21 modification was also detected, along with an increase in the level of pS4pS8 (lane 7). These data indicate that while Ble treatment of Sphase cells causes a higher level of DNA breaks compared to CPT treatment, it generates weaker RPA phosphorylation. These data also demonstrate that RPA is not subject to significant phosphorylation in response to all DNA breakage events. We take the results of these experiments to indicate that that the collision of DNA replication forks with trapped topoisomerase I complexes generates significant amounts of ssDNA that facilitate RPA phosphorylation.
Expression of the S23A/S29A-RPA2 mutant alters the cell cycle profile. Because S29 and presumably S23 are phosphorylated in response to genotoxic stress, we tested if expression of S23A/S29A-RPA2 had any gross biological effects. The cell cycle profiles of U2-OS clones replaced for wt-or S23A/S29A-RPA2 were examined by FACS (Fig.  6A ). Cells were tested both under normal conditions, and 12 h following a 3 h exposure to 4 µM CPT. In the absence of stress ('Normal'), a significantly greater fraction of cells expressing the mutant RPA2 were in the G2 phase as compared to cells expressing wt-RPA2. Following stress, both wt and mutant cells had a higher fraction in S phase (1.5 to 2.0 fold over nonstressed cells). This result is expected as U2-OS cells have an impaired G1/S arrest allowing cells with damaged DNA to enter S (47). CPT-induced damage would lead to an extended S phase as replication forks encounter unrepaired DNA. Even so, cells expressing the S23A/S29A-RPA2 mutant had a significantly higher level in S phase as compared to cells expressing wt-RPA2, and a reduced fraction in G2. These data suggest that, compared to cells expressing wt-RPA2, S23A/S29A-RPA2 cells had a greater level of DNA damage at later times following CPT treatment.
We examined the effect of RPA2 mutation on the formation of foci in the presence or absence of stress caused by CPT treatment. In untreated cells, those expressing wt-or S23A/S29A-RPA2 had apparently similar levels of RPA2 staining (Fig.  6B) . Following a 1 h exposure to CPT, RPA2 in apparent DNA damage foci showed a significantly greater immunofluorescence signal compared to untreated cells. Although a spectrum of RPA2 staining intensities was noted, it appeared that cells replaced for S23A/S29A-RPA2 had an average RPA2 staining intensity that was greater than that seen in cells expressing wt-RPA2. Cells representative of average staining patterns are shown (Fig. 6B) .
We quantitated the differences in RPA2 staining in cells that were fixed either 0 or 8 h following CPT treatment. In cells fixed immediately after treatment (0 h), a slightly greater fraction of S23A/S29A-RPA2 cells had robust RPA2-staining (39%; n = 224) compared to wt-RPA2 cells (34%; n = 322). Of these, cells expressing S23A/S29A-RPA2 had a significantly higher staining intensity (average = 54.8, mean = 53.6) compared to wt-RPA2 cells (average = 40.2, mean = 38.7) (Fig. 6C) . Eight h post-treatment, the fraction of cells with damage-dependent RPA2 staining increased slightly for both cell types (44% of wt-RPA2 cells [n = 294]; 45% of S23A/S29A-RPA2 cells [n = 265]), and the average RPA2 staining level in both cell types increased. However, cells expressing the mutant were seen to have more intense RPA2 staining intensity (average = 90.5, mean = 82.4) relative to wt-RPA2 cells (average = 59.1, mean = 53.1) (Fig. 6C) . These data suggest that, in response to CPT treatment, the phosphorylation site mutation impairs the ability of cells to repair the induced DNA damage, leading to higher levels of RPA binding.
Mutation of S23 and S29 Cdk sites inhibits
chromosomal DNA repair. We tested the hypothesis that RPA2 phosphorylation stimulates DNA repair. Cells replaced for either wt-or S23A/S29A-RPA2 were treated with CPT or Ble and then fixed immediately (0 h) or at 8 h posttreatment for CPT or at 15 h in the case of Ble. To assay for DNA damage, we quantitated the levels of γH2AX by immunofluorescence microscopy. Both the fraction of γH2AX-positive cells and the level of γH2AX staining were assayed.
Testing CPT, it was found that the RPA2 variant expressed had no significant effects on the fraction of cells showing significant γH2AX staining (Fig. 7A) . In contrast, the phosphorylation site mutation had a significant effect on the average γH2AX signal in the γH2AX-positive cells. For example, at 8 h following treatment, the relative γH2AX signal in cells expressing wt-RPA2 was 2.6 ± 1.7 units compared to 8.6 ± 4.0 units for S23A/S29A-RPA2 cells. Representative cells reflecting this >3-fold difference are shown (Fig. 7, panels B [wt-RPA2] and C [S23A/S29A-RPA2]). These data indicate that cells expressing the mutant RPA2 were defective in repair of CPTinduced lesions.
The RPA2 mutation also had effects following Ble treatment, with cells expressing S23A/S29A-RPA2 showing a significant increase in the fraction of cells that were γH2AX-positive (Fig. 7D) . Immediately following treatment (0 h), the percentage of S23A/S29A-RPA2 cells with significant γH2AX staining was two-fold higher than in wt-RPA2 cells (68.2 ± 0.1 vs. 32.2 ± 0.1, respectively). At 15 h post-treatment, the fraction of γH2AX-positive cells expressing S23A/S29A-RPA2 was >4-fold higher (37.0% ± 5.7 vs. 8.8% ± 0.1, respectively). Cells replaced for S23A/S29A-RPA2 also had a slightly higher level of γH2AX staining compared to cells expressing wt-RPA2. Interestingly, although the fraction of γH2AX-positive cells decreased at 15 h post-Ble treatment compared to immediately following treatment, the level of γH2AX staining in these positive cells was seen to increase, perhaps reflecting an increased fraction of cells with intense γH2AX staining. Representative images of the different γH2AX staining patterns seen at 15 h after Ble treatment is shown (Fig. 7 , panels E [wt-RPA2] and F [S23A/S29A-RPA2]). Images of untreated wt and S23A/S29A-RPA2 cells are also provided, which demonstrate that both cell types show a low basal level of γH2AX staining in the absence of exogenous stress (panel G). In sum, these data indicate that cells expressing RPA unable to undergo cyclin-Cdk phosphorylation are defective in repair of lesions induced either by Ble or CPT.
DISCUSSION
The significance of RPA phosphorylation has been unclear since its discovery nearly two decades ago. Our data demonstrate that the role of RPA phosphorylation is to stimulate chromosomal DNA repair. That is, cells expressing RPA2 mutated at two Cdk sites had increased γH2AX levels in response to either CPT or Ble. Treatment of such cells also caused a greater fraction to have an elongated S phase, compared to cells expressing wt-RPA2, and led to more intense RPA2 foci. We postulate that the inability of cyclin-Cdk to phosphorylate RPA2 impairs recruitment of specific DNA repair factors to DNA lesions. The defective ability of RPA to recruit these factors leads to longer retention of γH2AX foci, increased binding of RPA to damage DNA, and altered cell cycle progression.
A second significant conclusion of this study is that RPA phosphorylation in response to CPT treatment follows a preferred pathway involving both the cyclin-Cdk and PIKK families of kinases. The two kinase classes act synergistically to yield hyper-phosphorylated RPA that is modified on the extreme N-terminal S4 and S8 residues. The major observations are as follows: 1) S33 is phosphorylated by ATR (24; Vassin et al., unpublished data); 2) mutation of both of the cyclin-Cdk sites (S23A/S29A) causes a reduction of the pS33 signal in hyper-phosphorylated RPA2 yet retains a pS33 signal migrating slightly above non-phosphorylated RPA2 (e.g. , Fig. 4B); 3) RPA2 containing a S23D/S29D phospho-mimetic mutation restores hyper-phosphorylation; 4) mutation of T21 causes a loss of the pS29 signal from the hyper-phosphorylated form, while not significantly affecting the pS29 signal with an intermediate migration (Fig. 4C) ; 5) pT21 only migrates with hyper-phosphorylated RPA2 (e.g. ,  Fig. 4C ); 5) individual mutation of S33, S29, S23, and T21 all inhibit formation of pS4pS8, to varying degrees; and 6) test of the role of DNA-PK in this (see Fig. 3D ) and previous studies (22, 23) indicate that DNA-PK phosphorylates T21 and S4/S8.
We therefore propose the following scheme of RPA phosphorylation (Fig. 8A) . In response to CPT, ATR becomes activated and modifies S33. leads to final modification of S4 and S8, and perhaps residues within the S11, S12, and S13 cluster, by the action of DNA-PK. Lack of Cdk phosphorylation inhibits further RPA2 phosphorylation events, leading to the aforementioned effects on DNA repair.
While the large bulk of our data leads us to propose this model of a preferred pathway of RPA phosphorylation, this may not be the only pathway followed and other explanations are conceivable. For example, one could argue that phosphorylation of S23 and S29 is constitutive, but the modifications are normally removed by a phosphatase that becomes inhibited by S33 phosphorylation. However, such a model appears less likely because we do not detect pS29 outside of mitosis in non-stressed cells (see Fig. 2C ). We also emphasize that the pattern of phosphorylation, and the kinases we propose in our model (Fig.  8A) , were deduced from treatment of cells with CPT and are not meant to represent the pathway of events occurring in response to other genotoxic stresses or under all circumstances.
Our data also indicate that cyclin-Cdk and PIKK act synergistically in catalyzing RPA phosphorylation. That is, mutation of the two cyclin-Cdk sites inhibits phosphorylation of the two PIKK sites, and loss of the two PIKK sites reduces S29, and presumably S23, modification (Fig. 4B) . We hypothesize that this synergy exists in two forms, cis and trans. First, modification of particular residues on RPA2 stimulates phosphorylation of residues on the same RPA2 molecule (i.e., in cis; Fig. 8A ). This could conceivably be caused by the modified residue(s) stabilizing the binding of a kinase, thereby increasing the efficiency of another phosphorylation event (e.g., formation of pS33 facilitates S29 phosphorylation). In addition, our data also suggest that modification of one RPA molecule bound to ssDNA stimulates the phosphorylation of a different RPA molecule bound to the same ssDNA (Fig. 8B) . That is, we find that mutation of T21 affects modification of S29 and S33 even though formation of pT21 appears to occur after S29 and pS33 phosphorylation (i.e., pT21 is only found in the hyper-phosphorylated form). In addition, we also observe that loss of DNA-PK CS not only prevents T21 and S4/S8 modification but also generation of pS29 by cyclin-Cdk. From these data, we propose that phosphorylation of T21-RPA2 on one RPA molecule stimulates the phosphorylation of S33-RPA2 by ATR on a different RPA molecule in trans. Such a regulatory device would allow all of the RPA bound to a particular lesion to achieve a similar phosphorylation state. This notion is conceptually similar to the propagation of γH2AX outward from a DSB by ATM (e.g., ref. 48) .
The dual control of RPA phosphorylation by Cdk and PIKK members is reminiscent of a similar requirement for the cell-cycle dependent activation of ATR at DSBs. In this case, DSBs are resected by the Mre11 exonuclease in an ATMand Cdk-dependent process to generate ssDNA tails which are then bound by RPA (31) . The ATR-ATRIP complex loads onto the RPA-ssDNA structure leading to activation of the ATR kinase (28, 29) . A similar reaction occurs in budding yeast (49) . The co-regulation of ATR and RPA (i.e., both require upstream Cdk and PIKK activities) would be expected to facilitate coordination of these two factors in the signaling and repair of DNA damage. In other words, ATR activation or RPA phosphorylation alone would be unable to facilitate further downstream repair events. The need to simultaneously activate both factors for repair may serve as a check against spurious recruitment of DNA repair factors.
Our results extend those of Pan et al. examining RPA phosphorylation in extracts from HeLa cells prepared at different cell cycle phases (32) . These in vitro experiments led to the conclusion that phosphorylation of RPA2 by cyclin A-Cdk2 was critical for subsequent phosphorylation by DNA-PK. However, our in vivo study indicates that cyclin-Cdk is both facilitated by prior ATR action (at S33) and stimulates subsequent phosphorylation of other residues by DNA-PK (T21 and probably S4 and S8).
Use of various strategies (i.e., test of the Cdk inhibitor roscovitine and the MEK inhibitor U0126) lead us to conclude that the primary kinase that phosphorylates S29-RPA2 following CPT treatment is Cdk2. Because the phosphorylation occurs selectively in the S and G2 phases, and cyclin E-Cdk2 is unable to modify RPA in vitro (32, 39) , we postulate that the responsible kinase complex is cyclin A-Cdk2. Although increased phosphorylation of Cdk sites in response to genotoxic stress is rare, it is not unprecedented.
Human p53, for example, also contains a site (S315) that is apparently modified by cyclin ACdk2 in response to UV or ionizing irradiation (48, 50) . Although the general activity of cyclin ACdk2 decreases in response to stress, we detect S29-RPA2 phosphorylation at early times after DNA damage when cyclin A-Cdk2 would be expected to retain significant activity. Even so, it remains unclear why only a few cyclin A-Cdk2 substrates show increased modification in response to genotoxic stress. In the case of RPA, it is possible that phosphorylation of S33 creates a more favorable binding site for cyclin A-Cdk2, stimulating S23 and S29 modification. It is notable that the level of RPA phosphorylation in response to Ble is relatively low in G1, increases in S, and reaches a maximal level in G2 phase. DSBs in vertebrate cells are repaired by non-homologous end-joining (NHEJ) in G1 and early S phases, and by HR during late S and G2 phases (51). Because we find maximum RPA2 phosphorylation in cells treated with Ble in the late S and G2 phases, we speculate that these RPA species are selectively generated at DSBs repaired by HR -presumably when bound to the ssDNA formed after 5' to 3' resection of DSB ends. The weak phosphorylation of RPA in G1 cells treated with Ble may reflect the apparent lack of RPA in repair of DSBs by NHEJ. Hence, RPA phosphorylation may facilitate repair of DSBs by HR. We are currently exploring this possibility. Fig. 1 . hRPA2 phosphorylation sites and replacement strategy. A, the phosphorylation sites in the Nterminal region of RPA2 are indicated with underlines. The consensus sites for putative kinases are shown (beneath the sequence), as are the residues for which phospho-specific antibodies are available (above). B, RPA2 mutants tested in these studies. Of the nine different RPA2 mutants, the S23 and S29 aspartate mutants were only tested in the context of Myc-RPA2. The S23 and S29 alanine mutants were examined using both Myc-and untagged-RPA2, while the T21 and S33 mutants were only tested using untagged-RPA2. C, schema for RPA2 replacement and induction of genotoxic stress. To replace RPA2, individual stable cell clones were first induced to express the ectopic RPA2 variant by removal of doxycycline (Dox) from the media. After 48 h, cells were treated with an siRNA specific for the endogenous RPA2 message, to down-modulate the endogenous RPA2 protein. Three days following siRNA treatment, cells were harvested, or subjected to genotoxic stress conditions such as CPT treatment prior to harvest. D, induction profile of a representative stable cell clone expressing ectopic RPA2. A representative S29A-RPA2 U2-OS clone was incubated for 48 h in the presence (lane 1) or absence (lane 2) of doxycycline, followed by silencing for 72 h. Post silencing, cell lysates were analyzed by Western, by probing with an antibody against general RPA2. Non-silenced U2-OS cells was used as a control to compare endogenous and ectopic RPA2 expression (lane 3). For a protein loading control, a portion of the Ponceau S-stained transfer membrane is shown. Fig. 2 . Modification of S29 on RPA2. A, extracts prepared from CPT-treated cells (2 mM for 1 h) were subjected to lambda phosphatase treatment or mock treated in the presence of phosphatase inhibitors. Lysates were examined by Western blotting for pS33, pS29, pT21, and general RPA2. Western blots probed with the anti-pT21 antibody were later stripped and probed with a general RPA2 antibody. The Ponceau stain loading control is therefore identical for these two samples (indicated by a '*'). B, cloned U2-OS cells were induced to express untagged wt-or S23A/S29A-RPA2, using the strategy shown in Fig.  1C . Replaced cells were mock-treated, incubated with CPT (2 µM for 1 h), or incubated with nocodazole (100 ng/ml for 12 h). For cells treated with nocodazole, loosely attached cells were shaken off to isolate mitotic cells. Subsequent to all treatments, cell lysates were prepared and subjected to Western analysis using either an anti-pS29 or general RPA2 antibody. As a control, lysates were also probed with an anti-β-actin antibody. C, U2-OS cells were arrested with nocodazole, then released and harvested at different time points post-release. Cells collected at the various time points were analyzed by FACS, and the cyclecycle distribution is indicated at the bottom of the panel. Lysates were prepared from each cell sample, and analyzed by Western using anti-pS29-RPA2 and general RPA2 antibodies, as indicated. For both panels, 'H' refers to hyper-phosphorylated RPA2, 'M' indicates mitotic RPA2, and 'B' designates basal (i.e., non-phosphorylated) RPA2. D, mutation of S23 and S29 alters formation of mitotic RPA. U2-OS cells were individually transfected with Myc-tagged wt-RPA2 or the following RPA2 mutants: S23A, S29A, S23A/S29A, S23D, S29D, and S23D/S29D, as indicated. Post-transfection (48 h), cells were nocodazole-treated for 17 h. Mitotic cells were collected by shake off, lysates prepared and subjected to Western analysis using an antibody against the Myc epitope. The wt-RPA2 showed three distinct bands: B (basal), +1p, and +2p, the latter migrating similarly to mitotic (M) RPA2. Our data indicate that these species represent non-phosphorylated, mono-phosphorylated, and di-phosphorylated RPA2, respectively. pS29-, pT21-, and pS4/pS8-RPA2, as indicated. C, test of ERK1/2 in RPA2 phosphorylation. U2-OS cells were initially treated with 0, 5, or 10 µM U0126 for a period of 1 h, and then further incubated with 2 µM CPT for an additional 1 h. Lysates were prepared, subjected to SDS-PAGE, and probed by Western blotting using antibodies against ERK, phospho-ERK, pS29-RPA2, and RPA2 (general) antibodies. The images in panel C were taken from the identical blot and membrane, although extraneous lanes have been spliced out, yielding a composite figure. D, involvement of DNA-PK in RPA2 phosphorylation following genotoxic stress. Cell lines that are either wild-type (+; M059K) or null (-; M059J) for expression of DNA-PK CS were treated with 2 µM CPT for 1 h. Lysates were prepared and then probed for total RPA2 or specific phosphorylated RPA2 residues, as indicated. For panels B to D, a portion of the Ponceau S stain of the transfer membrane was used as a loading control. For all panels, RPA2 migration positions were indicated as follows: M, mitotic; H, hyper-phosphorylated; I, intermediate; L, low; and B, basal (i.e., non-phosphorylated). Fig. 4 . Inter-relationship of RPA2 phosphorylation events. A, lack of RPA2 phosphorylation in control (i.e., non-CPT treated) cells. Stable U2-OS clones were induced to express ectopic wt-, S23A-, S29A-and S23A/S29A-RPA2 (top), or wt-, T21A/S33A-, S33A-and T21A-RPA2 (bottom), and the endogenous RPA2 then down-modulated by RNAi. Lysates were prepared and analyzed by Western, using antibodies against total RPA2. B, comparison of the effects of double cyclin-Cdk or double PIKK site mutations. Stable U2-OS clones were induced to express wt-RPA2, T21A/S33A-RPA2, or S23A/S29A-RPA2, and the endogenous RPA2 down-modulated by use of a specific siRNA. These cells were then treated with 2 µM CPT for 1 h to induce a genotoxic stress response. Lysates were prepared and probed for the presence of total RPA2, pS33, pS29, pS4pS8-RPA2, and β-actin (loading control) as indicated. The relative level of each phosphorylated species (including L, I, and H forms) was determined by densitometric analysis of the Western blot image. For each sub-panel, the phosphorylation signal seen for wt-RPA2 was set at 1.0, and the relative fraction of the signal detected for each mutant was then determined. C, effect of single and double cyclin-Cdk site mutation on RPA phosphorylation. Same as panel B. D, the S23D/S29D-RPA2 mutation rescues the loss in hyperphosphorylation observed with S23A/S29A-RPA2. U2OS cells were transiently transfected with myc-tagged RPA2 (WT, S23D/S29D or S23A/S29A). Post-transfection (48 h), cells were mock-treated (lanes 1 to 3), or treated with 2 µM CPT for 1 h (lanes 4 to 6). Lysates were subjected to Western analysis using an anti-myc antibody. E, effect of single and double PIKK site mutation on RPA phosphorylation. Cells were analyzed identically as indicated in panel B. An image of the transfer membrane stained with Ponceau S was used to show protein loading for panels A, C, and D. An identical scheme as that described in the Figure 3 legend was used to indicate relative RPA2 migration. The images in individual panels were taken from the identical blots and membranes, although extraneous lanes have been spliced out, yielding a composite figure. Protein loading is shown using a portion of the Ponceau S-stained transfer membrane. The relative migration of the various RPA2 species is indicated using the same scheme as described in the Figure 3 legend. Fig. 6 . Expression of S23A/S29A-RPA2 alters the cell cycle profile and the response to DNA damage. A, FACS analysis of U2-OS cells 'replaced' for wt-or S23A/S29A-RPA2. Cells were examined in the absence of exogenous stress ('Normal'), and 12 h following a 3 h exposure to 4 µM CPT. To determine statistical significance, data from cells expressing wt-and S23A/S29A-RPA2 were analyzed using the Student's t-test (* indicates p < 0.05, while ** indicates p < 0.01), comparing either mock or CPT Fig. 7 . Mutation of RPA2 Cdk sites lengthens retention of γH2AX foci following genotoxic stress. Cells were silenced for endogenous RPA2 and ectopic RPA2 induced. Cells were then treated with 5 µM CPT (70 h post silencing) or 30 µg/ml Ble (56 h post silencing). Following a 2.5 h treatment, cells were washed twice with PBS and then fixed either immediately (0 h), or at 8 h (CPT) or 15 h (Ble) post-wash. Cells were stained for γH2AX and DAPI, and images captured by epifluorescence microscopy. The fraction of γH2AX-positive cells expressing wt-or S223A/S29A-RPA2, following treatment with CPT (A) or Ble (D), was quantitated manually by comparison to DAPI images (200 to 300 cells total). The average γH2AX signal per γH2AX-positive cell was quantitated using ImageJ software. B, C, E, and F, representative images of γH2AX and DAPI stained cells expressing either wt-(panels B and E) or S23A/S29A-RPA2 (panels C and F), either 8 h post-treatment with CPT (panels B and C) or 15 h posttreatment with Ble (panels E and F). G, images of control wt-and S23A/S29A-RPA2 expressing cells showing γH2AX and DAPI staining. In each paired image, cells expressing wt-RPA2 are shown in the upper left half, while S23A/S29A-RPA2 cells are shown in the lower right. In the absence of treatment, we observed that <1% of cells were γH2AX-positive regardless of the RPA2 variant expressed. Because these cells will have randomly variable levels of γH2AX and we plot the γH2AX signals in the γH2AX-positive cells, these signals were not quantitated. Fig. 8 . Model of RPA2 phosphorylation pathway in response to CPT. A, stimulation of phosphorylation in cis. RPA bound to ssDNA generated during DNA damage is phosphorylated at S33 of RPA2 by ATR. This phosphorylated molecule then serves as a substrate for modification by cyclin-Cdk at RPA2 sites S23 and S29, and then by DNA-PK at T21, S4/S8 and likely S11, S12 and S13. B, stimulation of phosphorylation in trans. An RPA molecule phosphorylated at S4, S8, and T21 can enhance the subsequent phosphorylation of an adjacent RPA molecule by ATR. - Anantha et al. Figure 7 
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